SP16 as a Therapeutic for COVID-19 Induced ARDS

计划入组 2 人 · 首次发布于 2021 年 11 月 26 日

Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)

计划入组 40 人 · 首次发布于 2020 年 5 月 6 日

Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS

计划入组 50 人 · 首次发布于 2020 年 4 月 17 日

SARS-CoV-2 vaccine

SARS-CoV-2

SARS-CoV-2 PLpro

Invivyd

United States

Cleo Diagnostics Ltd

Canada

MEREO BIOPHARMA 2 LIMITED

United Kingdom

European Medicines Agency Recommends Approval of Gohibic for SARS-CoV-2-Induced ARDS

InflaRx's Vilobelimab Receives Positive CHMP Opinion for SARS-CoV-2-Induced ARDS

InflaRx's Gohibic (vilobelimab) Receives European Commission Approval for SARS-CoV-2-Induced ARDS